Preclinical studies suggest that GCGR/GLP-1R/glucose-dependent insulinotropic polypeptide (GIP) receptor triple agonists may also prove useful for the therapy of diabetes and obesity1,16,19,20. This evidence concerns the gene GCGR and diabetes mellitus.